CVS to Narrow Medicare Advantage Networks, Extend McKesson Deal to 2032
CVS sits 24% above its 52-week low of $69.51.
Summary
CVS is making structural changes to its Medicare Advantage business for 2027, shifting Aetna toward HMOs and reducing PPO access to control rising medical and drug costs. The company is also expanding bundled prior authorization for cancer care to Medicaid members starting September 1, with a broader rollout across all business lines by 2027. Separately, CVS extended its drug distribution agreement with McKesson through June 2032, covering mail-order, specialty, retail, and distribution centers. These moves follow a strong Q2 and come as the company manages cost pressures and regulatory scrutiny. The network narrowing could impact membership and revenue mix, while the McKesson extension provides supply chain stability.
At the time of this announcement, CVS was trading at $86.54 on NYSE in the Trade & Services sector, with a market capitalization of approximately $110.6B. The 52-week trading range was $69.51 to $110.68. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.